Balyasny Asset Management
MIRM icon

Balyasny Asset Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Balyasny Asset Management’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.3M Sell
489,170
-49,861
-9% -$5.01M 0.07% 324
2026
Q1 		$49.8M Buy
539,031
+253,161
+89% +$23.8M 0.06% 350
2025
Q4 		$22.6M Sell
285,870
-31,280
-10% -$2.25M 0.03% 653
2025
Q3 		$23.3M Buy
+317,150
New +$20.2M 0.03% 654
2025
Q2 		– Sell
-26,816
Closed -$1.21M – 3149
2025
Q1 		$1.21M Buy
26,816
+8,083
+43% +$381K ﹤0.01% 1915
2024
Q4 		$775K Buy
+18,733
New +$781K ﹤0.01% 2046
2024
Q2 		– Sell
-10,016
Closed -$252K – 2906
2024
Q1 		$252K Buy
+10,016
New +$275K ﹤0.01% 2323
2023
Q4 		– Sell
-18,107
Closed -$572K – 2740
2023
Q3 		$572K Buy
+18,107
New +$496K ﹤0.01% 1716
2023
Q2 		– Sell
-10,250
Closed -$246K – 2595
2023
Q1 		$246K Buy
+10,250
New +$234K ﹤0.01% 2176

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Balyasny Asset Management's MIRM Position: Q2 2026 in Review

Balyasny Asset Management reduced its Mirum Pharmaceuticals (MIRM) stake by 9.3% in Q2 2026, selling an estimated $5.01M and leaving 489,170 shares worth $57.3M. The position accounts for 0.07% of the portfolio, ranked #324.

Balyasny Asset Management first reported a position in MIRM in Q1 2023 and has held it in 9 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Balyasny Asset Management held 489,170 shares of Mirum Pharmaceuticals worth $57.3M as of Q2 2026.
  • Balyasny Asset Management sold 49,861 Mirum Pharmaceuticals shares in Q2 2026, an estimated $5.01M.
  • Mirum Pharmaceuticals made up 0.07% of Balyasny Asset Management's portfolio in Q2 2026, its #324 holding.
  • Balyasny Asset Management first reported a position in Mirum Pharmaceuticals in Q1 2023 and has held it in 9 quarters since.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.